Skip to content

Author

N. Chalasani

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study.

BACKGROUND Glucagon-GLP-1 dual receptor agonists have shown promise in treating metabolic dysfunction-associated steatohepatitis (MASH). The aim of the IMPACT trial was to assess the effects of one such agent, pemvidutide, in patients with MASH and stage F2 or F3 fibrosis. We previously reported the 24-week primary end...

M. Noureddin, N. Alkhouri, R. Loomba et al. · 0 citations
Open access Sep 2026

Multi-target blood test for hepatocellular carcinoma early detection: a cross-sectional analysis of the prospective ALTUS study.

BACKGROUND & AIMS Globally, 350 million people are at risk for HCC. Ultrasound screening is recommended but is limited by poor early-stage sensitivity and low adherence. This study evaluated whether the multi-target HCC blood test (mt-HBT) demonstrates non-inferior sensitivity for early-stage HCC compared with ultrasou...

Binu V. John, M. Camardo, A. Singal et al. · 0 citations
Open access Sep 2026

Role of IFNL4 Genotype in Hepatic Inflammation and Fibrosis due to Metabolic Dysfunction-Associated Steatotic Liver Disease

Background and Aims: In patients infected with hepatitis C virus, genetic polymorphisms within or near the interferon lambda 4 gene (IFNL4) predict the risk of hepatic inflammation and fibrosis. Several studies have reported that these polymorphisms are also associated with inflammation and fibrosis in patients with fa...

Callie J. Zaborenko, Aaron Hakim, Tae-Hwi Schwantes-An et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.